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Background: A huge amount of associations among different biological entities (e.g., disease, drug, and gene) are
scattered in millions of biomedical articles. Systematic analysis of such heterogeneous data can infer novel
associations among different biological entities in the context of personalized medicine and translational research.
Recently, network-based computational approaches have gained popularity in investigating such heterogeneous
data, proposing novel therapeutic targets and deciphering disease mechanisms. However, little effort has been
devoted to investigating associations among drugs, diseases, and genes in an integrative manner.
Results: We propose a novel network-based computational framework to identify statistically over-expressed
subnetwork patterns, called network motifs, in an integrated disease-drug-gene network extracted from Semantic
MEDLINE. The framework consists of two steps. The first step is to construct an association network by extracting
pair-wise associations between diseases, drugs and genes in Semantic MEDLINE using a domain pattern driven
strategy. A Resource Description Framework (RDF)-linked data approach is used to re-organize the data to increase
the flexibility of data integration, the interoperability within domain ontologies, and the efficiency of data storage.
Unique associations among drugs, diseases, and genes are extracted for downstream network-based analysis. The
second step is to apply a network-based approach to mine the local network structure of this heterogeneous
network. Significant network motifs are then identified as the backbone of the network. A simplified network based
on those significant motifs is then constructed to facilitate discovery. We implemented our computational
framework and identified five network motifs, each of which corresponds to specific biological meanings. Three
case studies demonstrate that novel associations are derived from the network topology analysis of reconstructed
networks of significant network motifs, further validated by expert knowledge and functional enrichment analyses.
Conclusions: We have developed a novel network-based computational approach to investigate the heterogeneous
drug-gene-disease network extracted from Semantic MEDLINE. We demonstrate the power of this approach by
prioritizing candidate disease genes, inferring potential disease relationships, and proposing novel drug targets,
within the context of the entire knowledge. The results indicate that such approach will facilitate the formulization
of novel research hypotheses, which is critical for translational medicine research and personalized medicine.* Correspondence: yuzhang@som.umaryland.edu
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A large amount of associations among biomedical en-
tities are scattered in biomedical literature. Systematic
analysis of such heterogeneous data provides biomedical
scientists with unprecedented opportunities to infer novel
associations among different biological entities in the
context of personalized medicine and translational re-
search studies. MEDLINE (http://www.nlm.nih.gov/bsd/
pmresources.html), for instance, currently contains more
than 22 million citations of biomedical literature. Semantic
MEDLINE is a knowledge base consisting of associations
automatically extracted from MEDLINE by integrating
document retrieval, advanced natural language processing
(NLP), and automatic summarization and visualization
[1]. However, it is computationally challenging to perform
queries directly from Semantic MEDLINE where associa-
tions among different biomedical entities are very complex
yet sparse. It is also very difficult to investigate those asso-
ciations at a large scale. Advance informatics approaches
have the potential to fill gaps between knowledge needs of
translational researchers and existing knowledge discovery
services.
In Semantic MEDLINE, biomedical entities and associa-
tions are semantically annotated using concepts in the
Unified Medical Language System (UMLS) [2]. The se-
mantic information defined in the UMLS can be further
leveraged to extract associations among concepts in spe-
cific domains and identify domain patterns for specific
studies through advanced computational methods such as
network-based analysis.
In the last decade, network-based computational ap-
proaches have gained popularity and become a new
paradigm to investigate associations among drugs, dis-
eases, and genes. Applications of these approaches in-
clude disease gene prioritization [3-5], identification of
disease relationships [6,7] and drug repositioning [8,9].
However, majority of these approaches focus on rela-
tionships between only two kinds of entities (e.g., asso-
ciation between gene and disease). For instance, Hu and
Agarwar [10] created a human disease-drug network
based on genomic expression profiles collected from
the Gene Expression Omnibus (GEO) (http://www.ncbi.
nlm.nih.gov/geo/). In total, 170,027 interactions between
diseases and drugs were considered significant, including
645 disease-disease, 5,008 disease-drug, and 164,374 drug-
drug associations. These expression-based associations
among diseases and drugs could serve as a backend
knowledge base to facilitate discovery. Bauer-Mehren
et al. [11] developed a comprehensive disease-gene as-
sociation network by integrating associations from sev-
eral sources that cover different biomedical aspects of
diseases. The results indicate a highly shared genetic
origin of human diseases. Functional modules were also
detected in several Mendelian disorders as well as incommon diseases. To systematically analyze drug-disease-
gene relationships, Daminelli et al. [12] proposed a
network-based approach to predict novel drug-gene
and drug-disease associations by completing incom-
plete bi-cliques in the network. This approach holds
great potential for drug repositioning and discovery of
novel associations. However, the analysis was limited
to only certain associations among drugs, genes, and
diseases (e.g., drug-disease and drug-gene associations). A
network-based investigation of all pair-wise associations
among these entities is necessary to understand the com-
plexity of existing associations and to infer novel associa-
tions within the context of the whole knowledgebase.
Network-based computational approaches enable us
to analyze heterogeneous networks such as drug-disease-
gene networks by decomposing them into small sub-
networks, called network motifs (NMs) [13]. NMs are
statistically significant recurring structural patterns found
more often in real networks than would be expected in
random networks with the same network topologies. They
are the smallest basic functional and evolutionarily con-
served units in biological networks. Our hypothesis is that
NMs of a network are the significant sub-patterns that
represent the backbone of the network, which serves as
the focused portion out of thousands of nodes (e.g., drugs,
diseases, and genes,) [14,15]. These NMs could also form
large aggregated modules that perform specific functions
by forming associations in overlapping NMs.
In this paper, we propose a network-based compu-
tational framework to analyze the complex network
formed by a large amount of associations. We focus on
a heterogeneous drug-disease-gene network derived
from Semantic MEDLINE and investigated underlying
associations using network-based systems biology ap-
proaches. Three case studies demonstrate that our ap-
proach has potential to facilitate formulization of novel
research hypotheses, which is critical for translational
medicine research. In the following, we first present
Materials and methods. We then describe the results
and case studies in detail.
Materials and methods
To comprehensively investigate the integrated drug-
disease-gene network formed by associations available in
Semantic MEDLINE, we propose the following two-step
computational framework: (1) extraction and optimization
of drug-disease-gene network in Semantic MEDLINE; (2)
network topology analysis of this heterogeneous network
at two levels: statistics and degree distribution of high-
confidence association networks, and distinct pattern de-
tection at NM level. In this section, we first describe the
steps to extract association network data from MEDLINE
database, followed by a description of the proposed
network-based approach to investigate this heterogeneous
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the steps of the proposed approach.
Data sources and preprocessing
Extraction of association data from Semantic MEDLINE
Semantic MEDLINE currently contains more than 56
million associations extracted from MEDLINE citations
and consists of eight tables, including concepts, concept
semantic types, concept translations, predication, predi-
cation arguments, and sentences. Data from different
tables need to be joined in order to obtain information
for a particular association between two entities. The
database contains an all-embracing joined table that pro-
vides information about associations (source concept,
predicate, and object concept), and their source PubMed
IDs (PMIDs).
We optimize and reorganize the relevant data in
Semantic MEDLINE into the Resource Description
Framework (RDF) format. Based on the UMLS semantic
types and groups [16], we extract unique associations
among drugs, diseases, and genes, and represent them in
six views in relational database tables. We then use the
Web RDF transformation tool D2R server to convert
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Figure 1 Overview of the network-based computational framework fofile (http://d2rq.org/d2r-server). This mapping file spe-
cifies the mappings between those six relational data-
base table schemas and the output RDF graphs [17]. A
detailed description of this approach is described in our
previous work [18]. These six tables are used as prelim-
inary association data resources including all unique
associations from Semantic MEDLINE.
Data preprocessing using FDA-approved drugs in DrugBank
Since the extraction accuracy of associations in Semantic
MEDLINE is about 77% (precision is 76% to 96%, and
recall is 55-70%) [19], a filtering strategy is applied to
extract high-confidence association data using the FDA-
approved drug list from DrugBank, a database contain-
ing drug information and the corresponding drug target
and treatment indication information [20]. As of July 31
2012, the database contains 1,578 FDA-approved drug
entries, including 131 FDA-approved biotech drugs, and
1,447 FDA-approved small molecule drugs. We extract as-
sociations involving these FDA-approved drugs from each
drug-related association table. After manually removing
generic and nonsensical terms in the association tables
(e.g., gene, homologous gene, and protein), we limit the
drug-drug, drug-gene, and drug-disease associations ton c Medline







r an integrated drug-disease-gene network.
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on the filtered drug-gene and drug-disease associations,
we generate related gene and disease lists and then ob-
tained gene-gene, disease-disease, and gene-disease associa-
tions using these genes and diseases. This filtering strategy
enables us to focus on associations related to FDA-
approved drugs only in this study. These associations are
then analyzed by the proposed network-based approach.
Network motif analysis
Network motifs are topologically distinct subnetwork
patterns that are present more frequently in true net-
works than in random networks [21]. They are usually
well conserved and possess specific processing tasks in
same types of networks. For example, in gene regulatory
networks, the same set of network motifs have been
repeatly identified in diverse organisms from bacteria to
human [22]. The hypothesis is that network motifs were
independently selected by evolutionary processes in a
converging manner and have characteristic dynamical
functions [23]. This suggests that network motifs serve
as building blocks of in gene regulatory networks that
are beneficial to the organism.
In this study, we extend network motif analysis to the
disease-drug-gene network. Six different types of associ-
ations among drugs, diseases, and genes are integrated
into a heterogeneous disease-drug-gene network. In this
network, nodes represent biomedical entities stored in
the RDF triples (i.e., diseases, drugs, or genes in “subject”
and “object”), and edges represent associations between
two biomedical entities (i.e., relationships in “predicate”).
For simplicity, we consider all associations as undirec-
tional association relationships in this study, discarding
the directionality and types in the original RDF graph. In
other words, as long as there is an association between
two nodes, we consider there is an edge between these
two nodes. We hypothesize that even within such sim-
plified disease-drug-gene association network, network
motifs in the network can (1) represent basic inter-
relationships among diseases, drugs, and genes; (2) re-
flect a framework in which particular functions are
achieved efficiently. Specifically, we focus on three-node
network motifs in this disease-drug-gene network since
they are the building blocks for larger size network motifs
(number of nodes > 3) [24]. All connected subnetworks
containing three nodes in the association network are col-
lated into isomorphic patterns [25], and the frequency of
the patterns are counted. We also generated 1000 random
networks from the original network by switching edges
between vertices and preserving the number of edges be-
tween types of nodes (i.e., disease, drug and gene). By the
default of FANOMD algorithm, if the number of occur-
rences for each pattern is at least five in the real network,
which is significantly higher than randomized networks,the pattern is considered to be a network motif. Statistical
significance test is performed by computing the fraction of
randomized networks in which the pattern appears at least
as often as in the interaction network [24]. The z score is
calculated using the following equation:
Z ¼ Nreal− Nrandh i
σrand
ð1Þ
where Nreal is the number of times one three-node sub-
network is detected in the real network, Nrand is the
mean number of times this subnetwork is detected in
1000 randomized networks, and σrand is the standard devi-
ation of the number of times this subnetwork is detected
in randomized networks. The p value of a motif is the num-
ber of random networks in which it occurs more often than
in the original networks, divided by the total number of
random networks. A pattern with p ≤ 0.05 is considered
statistically significant. This network motif discovery pro-
cedure is performed using the FANMOD tool [26].
Construction of the core drug-disease-gene network
It has been shown that in gene regulatory networks, for
each network motif, the majority of matches overlap and
aggregate into homologous motif clusters [27]. Many of
these motif clusters largely overlap with modules of
known biological processes [28]. The clusters of overlap-
ping matches of these motifs aggregate into a superstruc-
ture that presents the backbone of the network and is
assumed to play a central role in defining the global topo-
logical organization. Accordingly, we aggregate matches of
significant network motifs into a core drug-disease-gene
network. In this core network, we investigate the distribu-
tion of the connectivity degree of different types of nodes.
Nodes with significantly larger number of links in the
network are called hub nodes, which is critical in the
information flow exchange throughout the entire network.
Results
An integrated drug-disease-gene network reconstructed
from Semantic MEDLINE
We constructed a drug-disease-gene network with the
following two steps:
First, we extracted unique association data from
Semantic MEDLINE. Using a use-case driven database
optimization approach developed in our previous work
[18], we extracted six different types of associations
from Semantic MEDLINE database. Table 1 shows basic
statistics of these six groups of associations. As illustrated
in Table 1, the number of unique associations (the Unique
Association column) for each type of associations is
significantly less than the number of total associations
(the Record column). Since the prediction accuracy of
Semantic MEDLINE is approximately 77% [29], we used a
Table 1 Statistics of the six extracted association types
Association type Record in Semantic MEDLINE Unique associations Associations involving
FDA-approved drugs
Unique entity number
Disease-Disease 2,516,049 843,221 1684 2,248
Disease-Gene 206,155 111,117 21,444 5,954
Disease-Drug 3,021,256 1,277,879 54,996 3,414
Drug-Gene 398,572 248,491 3758 1,451
Drug-Drug 4,780,394 1,900,576 266 382
Gene-Gene 108,035 49,593 2169 2,792
Total 11,030,461 4,430,877 84,317 7,2431
1This is the unique number of entities by summarizing all the associations.
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approved drugs for downstream network-based analysis.
Second, we constructed association related data involving
FDA-approved drugs. We applied the filtering strategy
discribed in the Materials and methods section to extract
association data involving FDA-approved drugs from the
unique association data set. As shown in the “Associations
Involving FDA-approved Drugs” column in Table 1, the
association number of each table was further reduced.
We used this focused association data to construct an
integrated disease-drug-gene network for downstream
network-based analysis.
Network topology analysis of the core drug-disease-gene
network
The network motif analysis was performed on the inte-
grated disease-drug-gene network obtained in SectionFigure 2 Degree distribution of three biomedical entities: drug, geneAn integrated drug-disease-gene network reconstructed
from Semantic MEDLINE. Since the network contains
thousands of associations among 865 drugs, 2791 genes,
and 3578 diseases (Table 1), it is too complex for a direct
visualization. We overcame this problem by identifying
enriched network motifs and interpreting them through
an enhanced visualization. Out of this heterogeneous
network consisting of 84,317 associations among 7,234 en-
tities (including drugs, diseases, and genes), five significant
network motifs were identified. Figure 2 presents de-
tailed statistics on these network motifs. The matches of
these network motifs were extracted and number of
matches for each network motif was counted (“Num-
ber of Matches” column in Figure 2).
Based on the network motifs identified in the analysis,
we constructed a core disease-drug-gene network aggre-
gated from significant network motif instances. We then, and disease.
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entities in the integrated network. Figure 3 represents
the degree distribution of disease, drug, and gene nodes
in the core drug-disease-gene network. All three distri-
butions follow the power-law distribution, indicating
that networks related to different types of nodes are
scale-free. The majority of the nodes in the network
have only a few (less than 10) links but few other
nodes have a large number of links. Such distributions
have been observed in many studies of biological(A
(B)
Figure 3 Subnetworks extracted from NM 1. (A) Overview of the subne
associated with “Malignant neoplasm of prostate” and “tumor growth”. (C)
infection” and “multicentric Castleman's disease”.networks [30]. Our analysis demonstrates for the first
time that in an integrated network consisting of het-
erogeneous associations, the scale-free network struc-
ture still holds. The hub nodes (i..e, the nodes have a large
number of links) can provide scientists future research
directions.
Local network structure: from network to network motif
The five significant network motif patterns in Figure 2
have strong biological meanings and could suggest)
(C)
twork, consisting of 126 diseases and 79 genes. (B) Subnetwork
Subnetwork associated with “communicable diseases”, “West Nile viral
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provided three case studies in the following sections to
illustrate results based on three significant network
motifs.
Case study 1 - prioritization of disease genes
We first investigated whether the network motif analysis
could help prioritize disease genes based on the associa-
tions between diseases and their surrounding genes. One
example is Network Motif 1 (NM 1) in Figure 2, in
which two diseases that are associated with each other
are also associated with one common disease gene. This
indicates that diseases identified to be associated in lite-
rature are more likely to share same associated disease
genes. To further investigate the relationships highlighted
by NM 1, We extracted all associations relationships
among 126 diseases and 79 genes in NM 1. In total, there
are 71 disease-disease, 853 disease-gene, and 3 gene-gene
associations (Figure 4(A)) in this subnetwork, suggesting
that diseases that are associated with each other are more
likely to associate with a group of common disease genes.
For instance in Figure 4(B), “Malignant neoplasm of pros-
tate” shares all 35 associated genes with “tumor growth”.
Similar findings have also been discovered in other studies
demonstrating same functional modules/pathways being
affected in similar diseases [6,31,32]. There are 10 genes
only associated to “tumor growth” in literature. Such in-
formation will help scientists generate testable hypotheses
of possible roles of these genes in prostate cancer research.
Another example is shown in Figure 4(C), where “commu-
nicable diseases” was identified to have common associ-
ated genes with both “West Nile viral infection” and
“multicentric Castleman’s disease”. Thirteen genes associ-
ated only with “communicable diseases” can be considered
as candidate disease genes for the other two diseases and
help scientists design future exploratory experiments. The
detailed network information is presented in Additional
file 1: File S1.
Case study 2 - inference of disease relationships
Very interestingly, we also identified another similar
disease-gene network motif in our analysis (NM 4). The
only difference between NM 1 and NM 4 is that NM 4
doesn’t have the associations between two diseases
themselves. We extracted all associations among 2,664
diseases and 1,122 genes in NM 4. In total, there are 860
disease-disease, 17,242 disease-gene, and 310 gene-gene
associations in this subnetwork (Figure 5(A)). Based on
the “guilt by association” rule – diseases similar to each
other are more likely to be affected by the same genes/
pathways, two diseases involved in the same NM 4 are
more likely to be similar/associated than other diseases
[6]. For instance in Figure 5(B), “Kidney Failure” and
“skin disorder” are associated with a group of fivecommon associated genes. A wide variety of different
skin disorders have been observed in patients with kid-
ney diseases [33]. One example is the “psoriasis” disease.
During the treatment of psoriasis with fumaric acid
derivatives, patients could develop acute kidney failure
[34]. In the subnetwork that consists of first neighbors
of these two diseases, psoriasis is also included and has
common associated genes with both “kidney failure” and
“skin disorder”. Some genes in the network are associ-
ated with one of these diseases only but not both. To
investigate enriched biological functions/processes, we
performed functional enrichment analysis on neighbor
genes of three diseases with Ingenuity Pathway Analysis
(IPA) Suite (http://www.ingenuity.com/). These genes are
enriched in kidney-related disease categories (Table 2).
Although a major portion of neighbor genes are related
to “skin disorder” or “psoriasis” only, they have been an-
notated with kidney related dysfunctions in the IPA
database. Given the fact that associations among thou-
sands of diseases are complex yet incomplete, the in-
ferred association relationships based on our network
motif-based analysis can mine the significant network
topology properties of association networks and guide
scientists to investigate significant association relation-
ships in future experiments. The detailed network infor-
mation is presented in Additional file 2: File S2.
Case study 3 – Drug repositioning
Network Motif 2 (NM 2) suggests another association
pattern between diseases and drugs, in which two dis-
eases associated with each other are targets for the same
drug. It has been shown by Suthram et al. [7] that diseases
with significant correlations based on mRNA gene expres-
sion data also share common drugs. This NM supports
the hypothesis that similar diseases can be treated by same
drugs, allowing us to make hypotheses for drugs reposi-
tioning purpose. We extracted all associations among 468
disease and 162 drugs in NM 2. In total, there are 279
disease-disease, 8,730 disease-drug, and 14 drug-drug
associations in this subnetwork (Figure 6(A)). We further
investigated whether any drugs or diseases were “hub”
nodes in this subnetwork. In Figure 6(B), “Alzheimer’s
Disease” and “nervous systems disorder” are hub diseases
surrounded by 51 FDA-approved drugs. Both diseases are
associated with 20 common drugs, while “nervous systems
disorder” has associations with additional 31 drugs. These
drugs can be considered repositioned for treatment of
“Alzheimer’s Disease” since it is a central nervous system
disorder characterized by the presence of neurofibrillary
tangles, neuritic plaques and dystrophic neurites in the
brain [35]. In Figure 6(C), we observed two “hub” drugs
surrounding by 129 diseases, 16 of which have associa-
tions with both drugs. Dobutamine is a sympathomimetic
drug used in the treatment of heart failure and cardiogenic
(A)
(B)
Figure 4 Subnetworks extracted from NM 4. (A) Overview of the subnetwork, consisting of 2,664 diseases and 1,122 genes. (B) Subnetwork
associated with “Kidney Failure” and “skin disorder”.




Figure 5 Subnetworks extracted from NM 2. (A) Overview of the subnetwork, consisting of 468 disease and 162 drugs. (B) Subnetwork
associated with “Alzheimer’s Disease” and “nervous systems disorder”. (C) Subnetwork associated with “Dobutamine” and “Doxorubicin”.
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apy. Chemotherapy side effects may increase the risk of
heart disease in cancer patients [36]. This series of under-
lying connections can provide clinicians potential side
effects related to certain drug treatment. This could take
years to study in the clinic to identify such side effects.
The results derived from our approach can serve as
in silico exploratory analysis to guide such studies. Thedetialed network information is presented in Additional
file 3: File S3.
Three-gene network motif (NM 3) was also identi-
fied in this heterogeneous network. This NM is a very
common motif pattern in the protein-protein inter-
action network or gene regulatory network [37,38], in-
dicating that NM detection analysis of heterogeneous
networks can identify significant NMs even enriched
Table 2 Enriched disease and disorder categories in IPA analysis
Category p-value Molecules
Renal Inflammation 6.62E-09 VEGFA,COL4A5,CD40LG,APCS,IL1RN,CLU,MYH9,COL4A4,VDR,ACTN4,NFKB1,TNF,FAS
Renal Nephritis 6.62E-09 VEGFA,COL4A5,CD40LG,APCS,IL1RN,CLU,MYH9,COL4A4,VDR,ACTN4,NFKB1,TNF,FAS
Congenital Heart Anomaly 3.41E-06 VEGFA,HSPG2,TRIM21,EDNRA,ECE1
Liver Cirrhosis 4.13E-06 ADAM17,CD40LG,C5AR1,EDNRB,BSG,PTAFR,TNF,CCR7
Glomerular Injury 5.22E-06 VEGFA,CLU,MYH9,ACTN4
Cardiac Infarction 6.38E-06 PON1,BCL2L1,CD40LG,IL1RN,HSPA1A/HSPA1B,CLU,TNNI3,TNF,LRP1
Renal Atrophy 7.66E-06 CD40LG,EDNRB,FGF23,EDNRA,VDR,AQP2
Liver Damage 9.94E-06 BCL2L1,NLRP3,BSG,IL1RN,NFKB1,TNF,FAS
Liver Proliferation 1.75E-05 VEGFA,SOCS3,EDNRB,IL1RN,EDNRA,NFKB1,TNF,FAS
Pulmonary Hypertension 3.13E-05 EDNRB,IL1RN,KIT,EDNRA
Liver Hepatitis 4.73E-05 BCL2L1,IL23A,TNF,CCR7,FAS
Liver Necrosis/Cell Death 6.57E-05 SOCS3,BCL2L1,CD40LG,IL1RN,HSPD1,NFKB1,TNF,FAS
Cardiac Inflammation 6.64E-05 IL33,CLU,TNNI3,IL23A,NFKB1,TNF
Heart Failure 6.76E-05 BCL2L1,CA2,TNNI3,VDR,NFKB1,TNF,AQP2,PRKCA
Hepatocellular Carcinoma 6.87E-05 VEGFA,CA2,BCL2L1,SOCS3,ADAM17,BSG,KEAP1,CLU,IGFBP3,S100A4,KIT,MKI67,TNF
Liver Hyperplasia/Hyperproliferation 6.87E-05 VEGFA,CA2,BCL2L1,SOCS3,ADAM17,BSG,KEAP1,CLU,IGFBP3,S100A4,KIT,MKI67,TNF
Renal Dysfunction 2.46E-04 BSG,FGF23,TNF
Cardiac Necrosis/Cell Death 3.17E-04 VEGFA,SOCS3,BCL2L1,S100B,HSPD1,TNF,LRP1,NAD+
Cardiac Hypertrophy 5.67E-04 IL33,ADAM17,S100A6,HSPA1A/HSPA1B,FGF23,EDNRA,DMD,VDR,NFKB1,TNF,PRKCA
Renal Necrosis/Cell Death 5.83E-04 BCL2L1,HSPA1A/HSPA1B,IGFBP3,CLU,PAX2,NFKB1,TNF,FAS,PRKCA
Liver Inflammation 8.62E-04 IL1RN,FOXP3,NFKB1,TNF,FAS
Kidney Failure 1.37E-03 VEGFA,SLC9A3,PKD2,MYH9,VDR,TNF,AQP2
Cardiac Proliferation 1.66E-03 ADAM17,KIT,TNF,PRKCA
Renal Dilation 1.67E-03 EDNRB,EDNRA,AQP2
Nephrosis 2.35E-03 CLU,ACTN4
Liver Fibrosis 2.48E-03 VEGFA,SOCS3,EDNRB,PKD2,EDNRA,NFKB1,TNF,CCR7
Renal Proliferation 2.48E-03 SOCS3,HSPG2,TJP1,HSPD1,TNF,CCR7
Increased Levels of AST 3.13E-03 TNF,FAS
Cardiac Fibrosis 4.69E-03 TNNI3,DMD,VDR,NFKB1,TNF,DIO3
Increased Levels of Albumin 5.63E-03 VEGFA
Liver Regeneration 5.85E-03 SOCS3,IL1RN,TNF
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association network.
Comparisons of network motifs from different networks
Since all five network motifs identified involve only two
out of three node types, we further investigated whether
the networks involving only two node types can generate
the same NMs. To accomplish that, we performed NM
analysis on disease-gene, disease-drug and gene networks
respectively. Not all NMs detected in the complete net-
work can be detected in disease-gene, disease-drug and
gene networks respectively (Additional file 4: File S4). The
results indicate that although the NMs don’t contain all
three different node types due to small NM size, theadditional associations still introduce additional informa-
tion in the NM detection analysis.
Discussion
Literature mining approaches have been successful to
extract associations among biological entities in the last
decade. However, such information is usually large, com-
plex and multidimentional, making it impossible for bio-
medical researchers to directly investigate such data. To
leverage the gap between knowledge needs of translational
researchers and existing knowledge discovery services, we
have proposed a network-based informatics approach to
investigate the underlying relationships among different













1 0.0096% 0.0035% 9.2982e-006 6.5 < 0.001 131
126 diseases 
and 79 genes
2 0.038% 0.025% 2.3404e-005 5.4 <0.001 522
468 disease and 
162 drugs
3 0.0075% 0.0055% 7.5124e-006 2.7 0.008 103
286 genes
4 5.9% 5.1% 0.004215 2.2 0.026 81105
2664 diseases 
and 1122 genes
5 0.032% 0.024% 4.1072e-005 2.0 0.032 437
432 disease and 
148 drugs
Figure 6 Statistics of significant network motifs. Node color: black – drug, green – disease, red – gene. Edge color denotes the associations
between different biomedical entities: black – association between disease and disease, yellow - association between disease and gene, green -
association between disease and drug, red - association between gene and gene.
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advantages in several aspects.
Our approach is one of the first attempts to investigate
the disease-drug-gene associations in an integrative man-
ner. To demonstrate the superiority of NM analysis on the
heterogeneous network, we performed NM analysis on
disease-gene, disease-drug and gene networks respectively
and compared results with the ones derived from the
complete disease-drug-gene network. Not all network mo-
tifs detected in the complete network can be detected in
disease-gene, disease-drug and gene networks respectively.
The results indicates that although NMs doesn’t contain all
three different node types due to their small size in this
study, the additional associations still introduce additional
information in the analysis. In addition, NM analysis of
such heterogeneous networks can extract and highlight the
hotspots in the network, leading experts in different fields
to generate testable hypotheses in their future research.
We are aware that there are many other network ana-
lysis approaches for both social networks and biological
networks. These approaches are designed for differentpurposes. For instance, biological networks can be inter-
rogated by their overall properties (e.g., average cluster-
ing coefficient and overall distributions of node degrees),
significant NMs, or clustered subnetworks/modules. In
this work, we focus on identifying statistically significant
three-node NM patterns that can help infer novel disease-
drug-gene relationships. The NM analysis can decompose
the whole heterogeneous network into smallest network
patterns that recurrently discovered in the network, con-
sidered as the backbone associations of diseases, drugs,
and genes. For instance, in NM 1 instances in Figure 2,
most of these NMs contain the first two same diseases,
while the third gene is different. By extracting all the asso-
ciations involving these two diseases from the original as-
sociation network, we found that while these two diseases
share a significant number of associated genes, they also
have some unique associations with other genes respect-
ively. Based on the assumption that similar diseases are
more likely to associate with same group (s) of genes or
involve same biological processes, the genes associated
only with one disease can be prioritized as candidate
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http://www.jbiomedsem.com/content/5/1/33disease genes of the second disease. Such inference could
only be possible through NM level analysis by considering
significant network patterns (i.e., NMs) as well as their
neighborhood in the whole network. In addition, since
these NMs are statistically significant subnetworks, they
represent the “real” signal from the network which usually
contains considerable amount of false positive associa-
tions, especially those from literature mining techniques.
Due to the limitation of computational resource, we didn’t
include the NMs with more than three nodes. We plan to
extend our work to NMs with more nodes (i.e., >3) when
the computational resource become available. We believe
that the proposed network-based approach can comple-
ment other existing network analysis methods and provide
researchers a unique way to look at these huge heteroge-
neous networks.
From our preliminary study [18], we found that Semantic
MEDLINE lacks of gene-gene associations since such
information usually are illustrated in the main text of
literature. Semantic MEDLINE contains gene-gene inter-
action data from PubMed literature abstracts (Figure 2).
We included all the associations in Figure 2 in our analysis.
However, the number of gene-gene association in Semantic
MEDLINE (2,169 high-confidence pairs) is relevantly small
comparing to other public databases (e.g., HPRD [4]). For
instance, we compared the gene-gene associations in
Semantic MEDLINE with those in HPRD, a manually
curated gene-gene association database in human [4].
The overlap between these two databases is very small
(about 10% associations of Semantic MEDLINE can be
found in HPRD). HPRD contains many more associa-
tions than Semantic MEDLINE (41,327 versus 2,169).
Therefore, we believe that combining Semantic MED-
LINE with other public resources (such as HPRD [39]
and STRING [40]) will increase the coverage of asso-
ciations and build a more comprehensive association
database. Using linked data approach, it will be relatively
easier to link our data graph with such databases.
Conclusions and future work
In this paper, we proposed a network-based computa-
tional framework to investigate integrated heterogeneous
network extracted from MEDLINE literature, including
associations among three major entity categories: drug,
gene, and disease. Five significant NMs were identified
and considered as the backbone of the entire network.
The potential biological meanings of each network motif
were further investigated. The results demonstrated that
the proposed approach holds the potential to 1) prioritize
candidate disease genes, 2) identify potential disease rela-
tionships, and 3) propose novel drug targets, within the
context of the entire knowledge. We believe that such
analyses can facilitate the process of inferring novel rela-
tionships between drugs, genes, and diseases. One futuredirection is to develop module-based approaches to
understand associations between different biomedical
entities. Modules are condensed subnetworks in a net-
work. Modules identified in heterogeneous networks
are a group of related diseases, drugs and genes, which
gives researchers a focused network view of the associ-
ation relationships among these entities. Topology ana-
lysis of heterogeneous networks using graphic theory
can also be applied in future studies, which can lead to
the identification of diseases/drugs/genes in the context
of association networks. Pathway level information
could also be integrated in future analyses to extend
current association network.
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